Botox 200 unit vials
Ended Awarded Last action
- Contract number
- SPE2DR26FSCB9
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $13,203
Award facts
- Contract value 100% obligated
- $13,203.20 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency (DLA) awarded a $13,203.20 firm fixed-price delivery order to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler headquartered in Park Ridge, Illinois, for the supply of BOTOX 200 Unit Vials. The award was issued on December 17, 2025, with an ultimate completion date of January 9, 2026, and requires performance at the awardee's Park Ridge facility. No set-aside designation was utilized in this competitive procurement. This delivery order is issued under DMS Pharmaceutical Group's larger Indefinite Delivery Contract (IDC) with the DLA, specifically the Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative, a $30.3 billion government-wide acquisition vehicle designed to streamline pharmaceutical procurement for Department of Defense healthcare operations.
DMS Pharmaceutical Group, registered in the System for Award Management since 2001, serves as a critical regional prime vendor contractor within the broader PPV-G GEN V framework, which was awarded on November 13, 2025, with a $499,999,999 ceiling value extending through December 31, 2036. The company's established pharmaceutical distribution capabilities span branded and generic prescription medications, biologics, specialty pharmaceuticals, and medical consumables, positioning it to fulfill diverse medical supply requirements for military healthcare facilities worldwide. As a single-award IDC contractor under the PPV-G GEN V program, DMS Pharmaceutical Group has demonstrated substantial performance capability through numerous delivery orders issued by the DLA Medical Supply Chain division, establishing the company as a reliable supplier within the federal military medical system.
Quick answers
Who was awarded contract SPE2DR26FSCB9?
SPE2DR26FSCB9 was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on December 17, 2025.
How much is contract SPE2DR26FSCB9 worth?
The government has obligated $13,203 on SPE2DR26FSCB9.
Is contract SPE2DR26FSCB9 an order under another contract?
Yes. SPE2DR26FSCB9 is a delivery order under SPE2DR25D9316, an indefinite delivery contract.
Was contract SPE2DR26FSCB9 competed?
The extent of competition for SPE2DR26FSCB9 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award